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Ginkgolide A attenuates homocysteine-induced
endothelial dysfunction in porcine coronary
arteries
Wei Zhou, MD, Hong Chai, MD, PhD, Andy Courson, BS, Peter H. Lin, MD, Alan B. Lumsden, MD,
Qizhi Yao, MD, PhD, and Changyi Chen, MD, PhD, Houston, Tex
Background: Homocysteine is an independent risk factor for atherosclerosis. The objective of this study was to investigate
whether ginkgolide A (GA), a major constituent of Ginkgo biloba, could block homocysteine-induced endothelial
dysfunction in porcine coronary arteries.
Methods: Porcine coronary artery rings were assigned to six treatment groups: control; homocysteine (50 mol/L);
low-dose (50 mol/L) or high-dose (100 mol/L) GA; and homocysteine plus low-dose or high-dose GA. After 24
hours’ incubation, the rings were analyzed for vasomotor function in response to a thromboxane A2 analogue (U46619),
bradykinin, and sodium nitroprusside. Endothelial nitric oxide synthase (eNOS) was studied by using real-time
polymerase chain reaction and immunohistochemistry analysis. Superoxide anion production was assessed by chemolu-
minescence analysis.
Results: Endothelium-dependent relaxation (bradykinin) was significantly reduced in ring segments treated with
homocysteine as compared with the control (P < .05). When homocysteine was combined with either low-dose or
high-dose GA, endothelium-dependent relaxation was markedly recovered. There was no significant difference in
maximal contraction (U46619) or endothelium-independent relaxation (sodium nitroprusside) among all groups. In
addition, superoxide anion production was increased by 113% in the homocysteine-treated group, whereas there was no
statistically significant difference between the control and GA/homocysteine groups. Furthermore, eNOS messenger
RNA and protein levels were substantially reduced in the homocysteine-treated group (P < .05), but not in the
GA/homocysteine combined groups.
Conclusions: Homocysteine significantly impairs endothelium-dependent vasorelaxation through oxidative stress and
downregulation of eNOS in porcine coronary arteries. GA effectively prevents homocysteine-induced endothelial
dysfunction and molecular changes in porcine coronary arteries. This study underscores the potential clinical benefits and
applications of GA in controlling homocysteine-associated vascular injury and cardiovascular disease. ( J Vasc Surg 2006;
44:853-62.)
Clinical Relevance: Homocysteine is an independent risk factor for atherosclerosis. This study showed that ginkgolide A,
a major constituent of Ginkgo biloba, effectively prevents homocysteine-induced endothelial dysfunction and molecular
changes in porcine coronary arteries. This study underscores potential clinical benefits and applications of ginkgolide A
in controlling homocysteine-associated vascular injury and cardiovascular disease.It is widely accepted that endothelium dysfunction is an
initial step of atherosclerosis by altering endothelium de-
pendent factors, modifying blood vessel permeability, and
changing platelet and leukocytes adhesions. Homocysteine
is an independent risk factor for atherosclerotic diseases. Stud-
ies have shown that plasma homocysteine levels correlate with
cardiovascular mortality in a concentration-dependent fash-
ion and that the relationship is strongest when total plasma
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doi:10.1016/j.jvs.2006.06.012homocysteine levels are more than 15 mol/L.1,2 The
basis for these results has been extensively investigated, yet
it is not fully elucidated. A growing body of evidence
supports that oxidative stress plays an important role in the
effects of homocysteine on the cardiovascular system.3 Our
earlier study also demonstrated that homocysteine signifi-
cantly impaired endothelium-dependent vasorelaxation,
decreased endothelial nitric oxide synthase (eNOS) immu-
noreactivity, and increased superoxide anion production in
porcine coronary arteries.4-6 Furthermore, our previous
studies showed that antioxidant-based pharmacotherapy
can effectively reduce homocysteine-induced endothelial
dysfunction and free radical production.6-9 These studies
imply an important future therapeutic strategy of using
antioxidant-based pharmacotherapy for counteracting the
detrimental effects of hyperhomocysteinemia.
Ginkgo biloba, one of the oldest living tree species,
referred to as “a living fossil” by Charles Darwin, is wide-
spread throughout the world. The extract from its leaves is
one of the most widely used herbal supplements and has
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have shown the potential benefits of Ginkgo biloba in car-
diovascular diseases through its protective roles against free
radical injury on the vascular endothelium.10-13 However,
to our knowledge, there are no studies of these extracts in
hyperhomocysteinemic patients, who often have endothelial
dysfunction.We therefore chose to study the effect of ginkgol-
ide A (GA) on the vascular endothelium—particularly the
potential effects on homocysteine-induced injuries. This is
a novel investigation. We hypothesized that Ginkgo biloba
and its active constituent, GA, could protect the endothe-
lium from homocysteine damage. Specifically, we studied
the effects of homocysteine and GA on vasomotor func-
tion, eNOS expression, and superoxide production in
porcine coronary arteries. This study may suggest a
potential clinical application of Ginkgo biloba in control-
ling homocysteine-associated vascular injuries.
MATERIALS AND METHODS
Chemicals and reagents. DL-Homocysteine, dimethyl
sulfoxide (DMSO), 9,11-dideoxy-11a, 9a-epoxymeth-
anoprostaglandin F2a (U46619), bradykinin, Ginkgo bi-
loba A (GA), Tri-Reagent, Tris-buffered saline solution,
and phosphate-buffered saline (PBS) solution were ob-
tained from Sigma (St Louis, Mo). Dulbecco modified
Eagle medium was obtained from Life Technologies, Inc
(Grand Island, NY). Porcine coronary artery endothelial
cell (PCAEC) growth medium was purchased from Cell
Applications Inc (SanDiego, Calif). Antibiotic-antimycotic
was obtained from Mediatech Inc (Herndon, Va). The
iScript cDNA Synthesis Kit and iQ SYBR Green SuperMix
Kit were obtained from Bio-Rad Laboratories (Hercules,
Calif). Antibody against human eNOS was obtained from
BD Transduction Laboratories (Lexington, Ky). The bio-
tinylated horse anti-mouse immunoglobulin G and avidin-
biotin complex kit were obtained from Vector Labs (Bur-
lingame, Calif).
Myograph analysis. The myograph system used in
our laboratory has been previously described.6-9 Fresh por-
cine hearts were harvested from young adult farm pigs (6-7
months old) at a local slaughterhouse, placed in a container
filled with cold PBS solution, and immediately transported
to the laboratory. The pig right coronary arteries were
carefully dissected and cut into multiple 5-mm rings. The
rings were then incubated in Dulbecco modified Eagle
medium (Invitrogen, Carlsbad, Calif) with different con-
centrations of GA and homocysteine (50 mol/L) at 37°C
with 5% carbon dioxide in a cell-culture incubator for 24
hours. The concentrations used were GA at 25, 50, and
100 mol/L. After the pilot study, the concentrations of
GA at 50 and 100 mol/L were determined for the re-
maining studies. The right coronary artery rings were di-
vided into six groups (eight rings per group): DMSO con-
trol (solvent control), homocysteine alone (50 mol/L),
low-dose (50 mol/L) or high-dose (100 mol/L) GA
alone, and homocysteine plus low-dose or high-dose GA.
After incubation, the artery rings were analyzed by myograph
analysis (Danish Myo Technology Organ Bath 700 MO,Aarhus, Denmark). Each ring was treated with a thrombox-
ane A2 analogue (U46619; 107 mol/L) to generate
maximal contraction. The relaxation dose-response curve
was generated by adding 60 L of five cumulative doses of
the endothelium-dependent vasodilator bradykinin (109,
108, 107, 106, and 105 mol/L) at 3-minute intervals.
Subsequently, endothelium-independent relaxation was in-
duced by adding sodium nitroprusside (105 mol/L).
Contractility and percentage of relaxation were calculated
according to the tension changes. The data of the coronary
artery rings from eight different pig hearts were averaged
and represented as one data point for statistical analysis.
Cell culture. PCAECs and PCAEC growth medium
were purchased fromCell Applications Inc. Cells were used
at passages 4 to 6. When PCAECs grew to 80% to 90%
confluence in six-well plates, they were treated with homo-
cysteine (50 mol/L) with or without different concentra-
tions (1, 10, 20, 50, or 100 mol/L) of GA for 24 hours.
In all groups, cells cultured in DMSO (0.5% vol/vol) alone
were used as solvent controls.
Real-time polymerase chain reaction. Total RNA
from culture PCAECs or porcine artery endothelial cells
was isolated by using Tri-Reagent according to the manu-
facturer’s instructions. Complementary DNA was gener-
ated by reverse transcription from messenger RNA
(mRNA) by using the iScript cDNA Synthesis Kit ac-
cording to the manufacturer’s instructions. Then the iQ
SYBR Green SuperMix Kit was used for real-time poly-
merase chain reaction (PCR). Glyceraldehyde-3-phos-
phate dehydrogenase (GAPDH), a housekeeping gene, was
used as an internal control for eNOS expression, to account
for variations in mRNA loading. The same total RNA, 1
g, was loaded for all samples. Porcine eNOS and GAPDH
primers were designed by using Beacon Designer (Primer
Biosoft Inc, Palo Alto, Calif). The eNOS primer sequences
were as follows: forward primer, 5=-CCCTACAACG-
GCTCCCCTC-3=; reverse primer, 5=-GCTGTCTGTGT-
TACTGGATTCCTT-3=. The GAPDH primer sequences
were as follows: forward primer, 5=-TGTACCACCAACT-
GCTTGGC-3=; reverse primer, 5=-GGCATGGACTGTG-
GTCATGAG-3=. Real time PCR was performed in an
iCycler iQ real-time PCR detection system. The thermal
cycle condition used for reverse transcription was as fol-
lows: 5 minutes at 25°C, 30 minutes at 42°C, and 5
minutes at 85°C. The conditions used for real-time PCR
were as follows: 3 minutes at 95°C, 40 repeats of 20
seconds at 95°C, and 1 minute at 60°C. Controls were
performedwith no reverse transcription (mRNA sample) or
water control for both eNOS and GAPDH to demonstrate
the specificity of the primers and the lack of DNA contam-
ination in samples. Sample cycle threshold (Ct) values were
determined from plots of relative fluorescence units vs PCR
cycle numbers during exponential amplification so that
sample measurement comparisons were possible. The rela-
tive expression for eNOS in each sample was normalized
against GAPDH, shown as 2[Ct(GAPDH)  Ct(eNOS)].
Immunohistochemistry. Rings of treated porcine
coronary arteries were fixed overnight in 10% neutral buff-
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processing. Samples were later embedded in paraffin, cut
into 5-m-thick cross sections, and mounted onto slides.
Sections were treated with 3% H2O2 in PBS (pH 7.4) for
10 minutes to quench the endogenous peroxidase activity.
After three 10-minute rinses in 0.1 mol/L PBS, sections
were incubated in monoclonal antibody against human
eNOS (1:1000) diluted in 0.1 mol/L PBS containing 5%
normal horse serum and 0.1% Triton X-100 overnight at
4°C. After another three 10-minute rinses in 0.1 mol/L
PBS, sections were incubated with biotinylated anti-mouse
immunoglobulin G (1:250) at room temperature for 40
minutes. For diaminobenzidine visualization, sections were
incubated in avidin-biotin-peroxidase solution at room
temperature for 1 hour, followed by 0.1% diaminobenzi-
dine and 0.003% H2O2 in Tris-buffered saline for 5 to 10
minutes. Sections were counterstained with hematoxylin
and eosin, coverslipped, and viewed on an Olympus
BX41 microscope (Olympus USA, Inc, Melville, NY).
Images were captured with an attached SPOT-RT digital
camera and software (Diagnostic Instruments Inc, Ster-
ling Heights, Mich).
Lucigenin-enhanced chemiluminescence analysis.
Levels of superoxide anion produced by endothelial cells
were detected by using the lucigenin-enhanced chemilumi-
nescence method with a Sirius Luminometer and FB12
software from Berthold Detection System GmbH (Pfor-
zheim, Germany). The rings were cut open longitudi-
nally and trimmed into approximately 5  5-mm pieces.
They were then rinsed briefly in a modified Krebs
HEPES buffer solution (120 mmol/LNaCl, 4.7 mmol/L
KCl, 1.18 mmol/L K2HPO4, 20 mmol/L HEPES, 2.5
mmol/L CaCl2, 1.17 mmol/L MgSO4, and 25 mmol/L
NaHCO3). An assay tube (12  75 mm) was filled with
500 L of Krebs HEPES buffer solution and 25 L of
lucigenin. After gentle vortexing, the vessel segments were
placed endothelium side down in the tubes. Time-based
reading of the luminometer was recorded by FB12 soft-
ware. The data in relative light units (RLU) per second for
each sample were averaged between 5 and 10 minutes.
Values of blank tubes containing the same reagents as the
vessel ring samples were subtracted from their correspond-
ing vessel samples. The area of each vessel segment was
measured with a caliper and used to normalize the data for
each sample. Final data are represented as RLU per second
per square millimeter.
Nitric oxide staining and flow cytometry assay.
PCAECs were harvested with 0.02% trypsin/ethylenedia-
minetetraacetic acid and adjusted to 1  106 cells per
fluorescence-activated cell-sorter tube. 3-Amino, 4-amino-
methyl-2’, 7’-difluorofluorescein Diacetate (DAF-FMDA)
(10 mol/L) was added to the tubes and incubated at
37°C for 20 minutes. Final samples were collected in 500
L of staining buffer and stored at 4°C. Samples were
analyzed with a FACScan and Cell Quest software (Becton
Dickinson, Franklin Lakes, NJ) within 24 hours of prepa-
ration. In each experiment, at least 10,000 events were
analyzed.Statistical analysis. Data from the different groups
were analyzed by using an unpaired Student t test (two
tailed; Minitab software, Sigma Breakthrough Technolo-
gies, Inc, SanMarcos, Tex). In addition, analysis of variance
was used to analyze the data of endothelium-dependent
relaxation in response to bradykinin. A P value .05 was
considered statistically significant. Data are reported as
mean  SE.
RESULTS
GA blocks homocysteine-induced endothelial dys-
function in porcine coronary arteries. The pilot study
usingGA at three different concentrations (25, 50, and 100
mol/L) showed that GA at 25 mol/L had minimal
improvement on homocysteine-induced effects, whereas
homocysteine combined with GA at 50 and 100 mol/L
showed marked recovery of homocysteine-induced vaso-
motor dysfunction. Therefore, the concentrations of GA at
50 and 100 mol/L were selected for further study. The
arterial rings were divided into six treatment groups:
DMSO control, homocysteine alone (50 mol/L), low-
dose GA (50 mol/L), high-dose GA (100 mol/L),
homocysteine combined with low-dose GA, and homocys-
teine combined with high-dose GA. There was no substan-
tial difference inmaximumvessel contractionor endothelium-
independent relaxation among all group s ( P  .05; Fig 1, A
and D). Conversely, endothelium-dependent vasorelax-
ation was significantly different between the homocysteine-
treated group and the controls. As shown in Fig 1, B,
precontracted arterial rings in the homocysteine-alone group
showed marked reduction in endothelium-dependent va-
sorelaxation (0.12%  0.47%, 4.2%  1.34%, 15.2% 
2.5%, 28.9%  3.6%, and 44.1%  3.3%) in response to
each cumulative dose of bradykinin (109 to 105 mol/L)
as compared with the controls. Furthermore, endothelium-
dependent relaxation was significantly impaired in rings
treated with homocysteine alone as compared with controls
(bradykinin 105 mol/L; Fig 1, C), whereas neither high-
dose nor low-dose GA alone affects endothelium-dependent
relaxation. Both GA/homocysteine combined groups
showed complete recovery of endothelium-dependent va-
sorelaxation.
GA blocks homocysteine-induced eNOS down-
regulation in porcine coronary arteries and PCAECs.
The levels of eNOS mRNA expression in porcine coronary
arteries were measured by using real-time PCR analysis.
The effects of homocysteine and GA on mRNA expression
in the treated arterial rings are demonstrated in Fig 2. The
homocysteine-alone group showed a 65% reduction of the
eNOS mRNA level as compared with controls (P  .05),
whereas the low- and high-dose GA groups had a level of
eNOS mRNA comparable to the control levels (P  .05).
In addition, although this was not statistically significant,
the low-dose GA/homocysteine combined group showed
partial improvement in the eNOSmRNA level, whereas the
high-dose GA/homocysteine combined group showed sig-
nificant recovery in the eNOS mRNA level compared with
the homocysteine-alone group (P  .05). In addition, we
ial ce
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real-time PCR analysis (Fig 3). Similarly, homocysteine
alone significantly decreased eNOS expression by 59% as
compared with controls (P  .05). GA cotreatment dose-
dependently improved eNOSmRNA levels. GA alone (100
mol/L) did not show any effect on eNOS expression.
The expression of eNOS protein in porcine coronary
arterial endothelium was depicted by using immunohisto-
chemical staining (Fig 4). The DMSO control group
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Fig 1. Effects of homocysteine (Hcy) and ginkgolide A
A, Contractility. The rings (eight per group) were cult
(50 mol/L) alone, low-dose GA (50 mol/L) alone
combined with low-dose or high-dose GA. There was
response toU46619 (107mol/L) among all groups (P
in response to cumulative doses of bradykinin demon
concentration of bradykinin increased. Both the low-dose
improvements in vasorelaxation compared with homocy
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groups showed significant impairments in vasorelaxation
low-dose and high-dose GA/homocysteine groups de
compared with homocysteine (P  .05) and were si
relaxation. There was no significant difference among a
laxation induced by sodium nitroprusside. EC, endothelshowed a strong positive staining pattern of eNOS on theendothelial layer of the arterial walls, in contrast to the poor
staining pattern of eNOS in the homocysteine-alone
group. It is important to note that both GA/homocysteine
combined groups showed strong positive staining patterns
similar to that of the control group; this indicated the
recovery of eNOS protein in the endothelial layer of the
GA/homocysteine-treated group.
GA blocks homocysteine-induced nitric oxide de-
crease in PCAECs. PCAECs were treated with homocys-
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and analyzed by using a flow cytometry assay (Fig 5). We
analyzed the percentages of DAF-FMDA–staining positive
cells. The homocysteine-alone group showed a 26% de-
crease in the nitric oxide level as compared with control,
and GA at 10, 20, 50, or 100 mol/L concentrations
effectively reversed the homocysteine-induced nitric oxide
decrease (P  .05). GA at 1 mol/L did not reverse the
homocysteine-induced nitric oxide decrease. We also mea-
sured the mean fluorescence intensity of DAF-FM DA–
staining positive cells. The homocysteine-alone group
showed a 38% decrease in the nitric oxide level as compared
with the control, and GA at a 50 or 100 mmol/L concen-
tration effectively reversed the homocysteine-induced nitric
oxide decrease (P  .05). GA at 1, 10, or 20 mol/L did
not significantly reverse the homocysteine-induced nitric
oxide decrease.
GA blocks homocysteine-induced superoxide anion
production in porcine coronary arteries. Levels of su-
peroxide anion produced by endothelial cells were deter-
mined by using lucigenin-enhanced chemiluminescence
(Fig 6). Superoxide anion was markedly increased (by
114%) in the homocysteine-treated groups, as demon-
strated by a significantly higher level of peak chemilumines-
cence (17.8 0.54 RLU · s1 · mm2; n 8) thanDMSO
control (8.37 1.49 RLU · s1 · mm2; n 8). Low-dose
or high-dose GA alone showed no effects on the level of
peak chemiluminescence as compared with control (10.9
0.51 RLU · s1 · mm2 and 11.4  1.63 RLU · s1 ·
mm2, respectively). Again, both low-dose and high-dose
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Fig 2. Effects of homocysteine (Hcy) and ginkgolide A (GA)
on endothelial nitric oxide synthase (eNOS) messenger RNA
(mRNA) levels in porcine coronary arteries. The levels of eNOS
mRNA expression in porcine coronary arteries were measured
by using real-time polymerase chain reaction analysis. The
relative expression for eNOS in each sample was normalized
against glyceraldehyde-3-phosphate dehydrogenase (GAPDH).
The homocysteine-alone group showed a marked reduction in
eNOS mRNA levels as compared with the control, and GA dose-
dependently improved eNOS mRNA levels in the GA/homocys-
teine groups. DMSO, Dimethyl sulfoxide.GA/homocysteine combined groups showed a substantialreduction in superoxide anion level compared with ho-
mocysteine alone, as demonstrated by a dramatically
decreased level of peak chemiluminescence (12.34 
0.31 RLU · s1 · mm2 and 12.54  3.51 RLU · s1 ·
mm2, respectively).
DISCUSSION
Ginkgo biloba has a long history of clinical use with a
potential benefit in cardiovascular disease, but the underly-
ing mechanisms are not yet elucidated. This study investi-
gated the cellular mechanism and the functional influence
of GA, one of the major constituents of Ginkgo biloba, in
protecting against homocysteine-induced endothelial dam-
age. The study underscores that GA attenuates homocys-
teine-induced vasomotor dysfunction, eNOS downregula-
tion, and free radical production. These results suggest the
potential clinical application of ginkgo and its major con-
stituents in protecting endothelium against homocysteine
and superoxide-associated injuries and, thus, their potential
role in cardiovascular disease prevention.
Homocysteine is a known risk factor for cardiovascular
disease. Severe hyperhomocysteinemia (100 mol/L)
has been seen in patients with homozygous deficiency of
cystathionine -synthase or methylene tetrahydrofolate re-
ductase and is usually associated with premature arthroscle-
rosis or thrombosis. Even mild to moderate increases of
homocysteine (10-100 mol/L) are associated with in-
creased risks for cardiovascular and cerebrovascular dis-
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Fig 3. Effects of homocysteine and ginkgolide A (GA) on endo-
thelial nitric oxide synthase (eNOS) messenger RNA (mRNA)
levels in porcine coronary artery endothelial cells (PCAECs). The
levels of eNOS mRNA expression in PCAECs were measured by
using real-time polymerase chain reaction analysis. The relative
expression for eNOS in each sample was normalized against
glyceraldehyde-3-phosphate dehydrogenase (GAPDH). The homo-
cysteine-alone group showed a marked reduction in eNOS mRNA
levels as compared with the control, and GA dose-dependently im-
proved eNOS mRNA levels in the GA/homocysteine groups. GA
alone did not show any effect on eNOS expression.DMSO,Dimethyl
sulfoxide.eases. Eberhardt and colleagues14 demonstrated that mild
rong
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vasodilatation by increased reactive oxygen species and a
subsequent loss of nitric oxide bioavailability in an animal
model. Similar findings have been validated by Lang
et al15 and Tawakol et al.16 Our previous investigations
also confirmed that homocysteine significantly decreased
endothelium-dependent vasorelaxation and eNOS im-
munoreactivity and induced marked endothelial injury in
both porcine coronary and carotid arteries.4,6-9 Multiple
studies have shown that Ginkgo biloba reduces vasospasm
and induces endothelium-dependent relaxation. Nishida
and Satoh17 demonstrated that all constituents of Ginkgo
Fig 4. Effects of homocysteine (Hcy) and ginkgolide A
reactivity in porcine coronary arteries. A, The dimethyl
staining pattern of eNOS on the endothelial layer of the a
staining pattern of eNOS. The low-dose and high-dos
GA/homocysteine combined groups (E-F) showed a stbiloba extract had the concentration-dependent vasorelax-ant effect on rat aortic ring strips, although the constituents
had complicated interactions with each other. Similarly,
Delaflotte and colleagues18 showed the vasorelaxation ef-
fects of Ginkgo biloba on isolated rabbit aorta and demon-
strated that relaxation was mediated in part by factors
released from the endothelium. Furthermore, Auguet and
Clostre19 demonstrated that G i nkgo biloba increased relax-
ation in isolated rabbit aorta after the rapid phase of contrac-
tion and inhibited the slow phase of contraction after norepi-
nephrine induction. Their findings were confirmed by Chen
et al,20,21 who demonstrated that the vasorelaxati o n effects of
Ginkgo biloba on rabbit aortic rings and porcine basilar
) on endothelial nitric oxide synthase (eNOS) immuno-
xide (DMSO) control group showed a strong positive
l wall. B, The homocysteine-alone group showed a poor
-alone groups (C-F) and the low-dose and high-dose
positive staining pattern similar to the control group.(GA
sulfo
rteria
e GAarteries were mediated via the nitric oxide pathway.
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Fig 5. Effects of homocysteine (Hcy) and ginkgolide A (GA) on nitric oxide production in porcine coronary artery
endothelial cells. Cells were stained with the fluorescent dye 3-Amino, 4-aminomethyl-2’, 7’-difluorofluorescein
Diacetate (DAF-FM DA) and analyzed by using flow cytometry assay. A, Representative histograms of the flow
cytometry assay. B, Percentages of DAF-FMDA–staining positive cells. The homocysteine-alone group showed a 26%
decrease in the nitric oxide level as compared with control, and GA at a 10, 20, 50, or 100 mol/L concentration
effectively reversed the homocysteine-induced nitric oxide decrease (P  .05). GA at 1 mol/L did not reverse the
homocysteine-induced nitric oxide decrease. C, Mean fluorescence intensity of DAF-FM DA–staining positive cells.
The homocysteine-alone group showed a 38% decrease in the nitric oxide level as compared with control, and GA at 50
or 100 mmol/L effectively reversed the homocysteine-induced nitric oxide decrease (P  .05). GA at 1, 10, or 20
mol/L did not significantly reverse the homocysteine-induced nitric oxide decrease. DMSO, Dimethyl sulfoxide.
FL1-H, a fluorescence channel used in flow cytometry.
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sen for this study is relevant to clinical plasma levels of mild
to moderate hyperhomocysteinemia. Homocysteine at 50
mol/L was able to induce impairment of endothelium-
dependent relaxation without affecting endothelium-
independent relaxation or smoothmuscle contraction. The
results on homocysteine-induced vasomotor dysfunction
from this study are consistent with our previous studies
in that homocysteine significantly impaired endothelium-
dependent relaxation induced by bradykinin and exerted no
significant effect on maximal contraction or endothelium-
independent relaxation induced by thromboxane analogue
and sodium nitroprusside, respectively.6-9
Our pilot study showed that the effects of GA on
homocysteine-induced vasomotor dysfunction were con-
centration dependent. At 25 mol/L, GA showedminimal
effects on homocysteine-induced vasomotor dysfunction,
whereas GA at 50 and 100 mol/L effectively blocked the
effects of homocysteine on endothelium-dependent re-
laxation without affecting endothelium-independent re-
laxation. Additionally, our study showed that GA dose-
dependently attenuated the effects of homocysteine on
PCAECs. To further investigate the mechanism and effects
of GA and homocysteine on endothelial cells, GA concen-
trations of 50 and 100 mol/L were chosen. Our study
confirmed that GA by itself had no effect on the vasomotor
function of porcine coronary arterial rings. However, when
combined with homocysteine, both the high-dose (100
mol/L) and low-dose (50 mol/L) GA/homocysteine
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Fig 6. Effects of homocysteine (Hcy) and ginkgolide A (GA) on
superoxide anion production in porcine coronary arteries. Super-
oxide anion was markedly increased in the homocysteine-treated
groups as compared with the dimethyl sulfoxide (DMSO) control
(P .05). High-dose or low-dose GA alone showed no effects on
the level of peak chemiluminescence as compared with the control.
Both the high-dose and low-dose GA/homocysteine combined
groups showed a substantial reduction in superoxide anion levels.
RLU, Relative light unit.combined groups had a complete recovery of endothelium-dependent vasorelaxation. Our vasomotor study indi-
cates a potential clinical application of GA in preventing
homocysteine-induced vascular dysfunction.
Molecular mechanisms of homocysteine-induced en-
dothelium dysfunction have been extensively studied.Oxida-
tive stress and eNOS reduction have been proven to be the
major mechanisms through which homocysteine exerts its
effects on vascular endothelial cells.4,14,22 In this study, we
investigated the molecular mechanisms of homocysteine-
induced endothelial dysfunction by studying eNOS
mRNA and protein production by using real-time PCR
and immunohistochemical staining. To increase the
quality of measurement, we used internal controls to
ensure that an equal amount of tissue samples was mea-
sured for the study among all groups. The housekeeping
gene GAPDH was used as the control in real-time PCR
analysis. All the values were normalized before final
analysis. The homocysteine-treated group showed a
marked reduction of eNOS mRNA levels as compared
with the control group, and a decreased eNOS protein
expression in the porcine coronary arterial endothelium
was depicted by immunohistochemical staining. Al-
though this was not statistically significant, the low-dose
GA/homocysteine combined group showed a partial
improvement in eNOS mRNA levels, whereas the high-
dose GA/homocysteine combined group showed a sig-
nificant recovery of eNOS mRNA levels (P  .05).
Furthermore, immunohistochemical staining for eNOS
protein showed similar results. Endothelial NOS immu-
noreactivity was evaluated by gross observation of color
intensity. Quantitation was not performed because of
technique difficulties and the variability of staining.
More reliable quantitative methods, such as Western blot
for eNOS protein, may be warranted for studying the
effects of homocysteine and GA on eNOS expression in
coronary arteries. Nonetheless, our findings imply that
GA protects the endothelium from homocysteine-in-
duced damage with little effect on the healthy endothe-
lium. Further studies are needed to define the underlying
mechanisms of homocysteine and GA on endothelial
cells.
Our study also investigated the effects of GA and
homocysteine on free radical production in porcine coro-
nary arterial rings by using lucigenin-enhanced chemilumi-
nescence. Free radicals have been shown to play a key role in
atherosclerotic plaque formation and to be involved in
various vascular injuries. Several animal studies have shown
the efficacy of Ginkgo biloba against free radical damage of
the vascular endothelium. Szabo et al23 investigated the
effects of Ginkgo biloba in male Sprague-Dawley rats and
demonstrated that Ginkgo biloba, like superoxide dismutase,
significantly reduced the development of reperfusion-induced
retinal edema and prevented neutrophil leukocyte infiltra-
tion when administered just before reperfusion. Similarly,
Welt et al24 documented the protective properties of Ginkgo
biloba extract on endothelial cell ultrastructure, which was
evident by decreased edema, luminal blebs, and pericapil-
lary debris during acute hypoxic stress on myocardial mi-
JOURNAL OF VASCULAR SURGERY
Volume 44, Number 4 Zhou et al 861crovessels of old rats. Additionally, Wei and colleagues12
confirmed that Ginkgo biloba directly scavenged H2O2 in a
cell-free system and decreased H2O2 levels in pulmonary
artery endothelial cells. We further demonstrated that the
homocysteine-treated group showed a significant increase
in free radical production, whereas GA significantly re-
versed the effect of homocysteine, as indicated by dramat-
ically decreasing levels of peak chemoluminescence in the
GA/homocysteine combined groups. Our study proved
that either high-dose or low-dose GA can significantly
reverse homocysteine-induced free radical production.
Consistent with our previous studies,6,7,9 GA, similar
to ginsenoside Rb1, red wine, and estrogen, effectively
reduced homocysteine-induced endothelial dysfunction
and free radical production. These studies imply poten-
tial therapeutic strategies of using antioxidant-based
pharmacotherapy to counteract the detrimental effects of
hyperhomocysteinemia. Comparing the therapeutic
magnitude of each agent may enhance our knowledge of
these agents. However, each agent was studied under
specific conditions with a concurrent local control. Many
laboratory variables may influence endothelial function,
and this likely invalidates the comparison. Additionally,
there are no dose-dependent relationships among the
several agents that we studied previously, because differ-
ent concentrations were used for each agent according to
its dose-dependent effects on endothelial cells. Future
studies to explore the common pathway of these agents
are warranted.
Admittedly, mechanisms of homocysteine-induced en-
dothelial damage are not yet fully elucidated. Our results
indicate that other cellular pathways may be involved in the
functional effects of homocysteine that are not influenced
by GA. As demonstrated by our data, both low- and high-
dose GA significantly reversed the superoxide anion pro-
duction induced by homocysteine in the homocysteine/GA
combined groups, whereas low-dose GA only partially recov-
ered the eNOS mRNA level, which did not reach statistical
significance. Furthermore, the endothelium synthesizes a
variety of vasodilators and vasoconstrictors. It is the ulti-
mate balance between these and the external stimuli that
determines the endothelial function. Further studies are
needed to investigate the detailed molecular and cellular
mechanisms of GA, as well as other endothelial-dependent
factors that may play a role in endothelial dysfunction.
CONCLUSION
This study demonstrated that GA effectively blocks
homocysteine-induced impairment of endothelium vaso-
motor function in porcine coronary arteries. In addition,
GA successfully improved homocysteine-induced reduc-
tion of eNOS mRNA, protein levels, and nitric oxide
production, as well as superoxide anion overproduction.
This study demonstrated the functional relationship and mo-
lecular mechanisms of the effects of GA on homocysteine-
induced endothelial damage. However, the observations
made during this investigation do not directly translate into
human arteries, and there is extremely limited study in theliterature regarding serum levels of GA after oral doses in
humans. Therefore, future clinical studies are warranted to
determine the effects of GA on human endothelium and to
determine the optimal oral dose of GA and Ginkgo biloba.
Consistent with our previous studies, GA, similar to gin-
seng, red wine, and estrogen, effectively reduces homo-
cysteine-induced endothelial dysfunction and free radi-
cal production. These studies imply an important future
therapeutic strategy of using antioxidant-based pharmaco-
therapy to counteract the detrimental effects of hyperhomo-
cysteinemia. Moreover, antioxidant-based pharmacotherapy,
perhaps, also has a protective role in other free radical–induced
vascular injuries.
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